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GenomeA B S T R A C T
Mycobacterium aurum (M. aurum) is an environmental mycobacteria that has previously
been used in studies of anti-mycobacterial drugs due to its fast growth rate and low
pathogenicity. The M. aurum genome has been sequenced and assembled into 46 contigs,
with a total length of 6.02 Mb containing 5684 annotated protein-coding genes. A phyloge-
netic analysis using whole genome alignments positioned M. aurum close to Mycobac-
terium vaccae and Mycobacterium vanbaalenii, within a clade related to fast-growing
mycobacteria. Large-scale genomic rearrangements were identified by comparing the M.
aurum genome to those of Mycobacterium tuberculosis and Mycobacterium leprae. M. aurum
orthologous genes implicated in resistance to anti-tuberculosis drugs in M. tuberculosis
were observed. The sequence identity at the DNA level varied from 68.6% for pncA (pyraz-
inamide drug-related) to 96.2% for rrs (streptomycin, capreomycin). We observed two
homologous genes encoding the catalase-peroxidase enzyme (katG) that is associated with
resistance to isoniazid. Similarly, two embB homologues were identified in the M. aurum
genome. In addition to describing for the first time the genome of M. aurum, this work pro-
vides a resource to aid the use of M. aurum in studies to develop improved drugs for the
pathogenic mycobacteria M. tuberculosis and M. leprae.
 2015 Production and hosting by Elsevier Ltd. on behalf of Asian African Society for
Mycobacteriology.pel Street,
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Mycobacterium aurum (M. aurum) is an acid-fast, gram-positive
environmental bacteria typically found in damp conditions
[1,2]. It is a fast-growing mycobacterium with an in vitro dou-
bling time of 2–3 h that rarely causes infections in humans [2–
6]. The M. aurum cell wall contains mycolic acids which are
analogous to those found in Mycobacterium tuberculosis [7],
and there are similarities between the antibiotic susceptibility
profiles of the two organisms [8,9]. The fast growth rate and
low pathogenicity of M. aurum have encouraged its use as a
surrogate for the highly pathogenic M. tuberculosis in studies
of anti-microbial activity of anti-tubercular drugs [6,10,11].
Unlike other fast-growing mycobacteria, such as
Mycobacterium smegmatis, M. aurum has the ability to survive
within macrophages [12,13] and has been used for high
throughput intracellular drug screening, allowing assessment
of the ability of compounds to permeate the cell membrane
and their stability within the cell [14,15]. The emergence of
strains of M. tuberculosis resistant to multiple first- and
second-line drugs threatens efforts to control tuberculosis
(TB) and has renewed interest in the search for new anti-
tubercular agents [16]. Rapid-growing models for screening
putative anti-tubercular compounds are needed to accelerate
drug discovery studies. Similarly, surrogate bacteria are
needed to enable studies on drugs that may improve treat-
ment for infection with non-culturable Mycobacterium leprae.
Knowledge of the bacterial genome could enhance under-
standing of the molecular basis for drug resistance, and to
this end, the genome of M. aurum has been sequenced and
annotated. The genome was placed in a mycobacterium phy-
logeny, and comparisons with M. tuberculosis, M. leprae and M.
smegmatis genomes were made in relation to susceptibility
towards anti-tubercular drugs.
Materials and methods
M. aurum sample and DNA extraction
The M. aurum (NCTC 10437) was grown in 7H9 Middlebrook
broth (Becton Dickinson, USA) supplemented with 10% albu
min–dextrose–catalase (ADC) at 35 C. DNA was extracted
using the Bilthoven RFLP protocol [17]. In brief, log phase
growth bacteria were treated with lysozyme, sodium dodecyl
sulphate, proteinase K, N-cetyl-N,N,N-trimethyl ammonium
bromide (CTAB) and chloroform-isoamyl alcohol prior to pre-
cipitation with isopropanol. Minimum inhibitory concentra-
tion (MIC) values for ethambutol, isoniazid, pyrazinamide
and rifampicin drugs for the same M. aurum strain are avail-
able [18]. Duplications in M. aurum of embB and katG loci were
confirmed by Sanger sequencing. For details of primers used,
see Supplementary Table 1.
DNA sequencing and genome assembly
The M. aurum genomic DNA was sequenced using a 101 bp
paired-end library on the Illumina HiSeq2000 platform. ThePlease cite this article in press as: J Phelan et al. The draft genome of Myc
against Mycobacterium tuberculosis and Mycobacterium leprae. Int. J. Mraw sequence data (size 0.55 Gb, 5.5 million paired reads,
greater than 99%) underwent de novo assembly using SPAdes
software [19]. The SSPACE software [20] was applied to scaf-
fold the assembly, and a combination of IMAGE [21] and
GapFiller [22] routines were used to further close or reduce
the length of remaining gaps. An alternative approach using
Velvet assembly software [23] led to a near identical assembly.
Genomic annotation was transferred to the draft genome
using the Prokka pipeline [24]. The pipeline searches for genes
present in contigs and compares them with protein and DNA
databases to annotate them. The cd-hit software [25,26] was
used to integrate the annotation from 8mycobacterial species
to create a non-redundant blast ‘‘primary’’ database used by
the Prokka pipeline. To validate the draft assembly and anno-
tation pipeline, the transferred annotation was compared
against the kas operon sequence (GenBank: DQ268649.2). All
5 genes from the GenBank entry (fabD, acpM, kasA, kasB,
accD6) were annotated in the correct order and orientation
in the assembly.Comparative genomics
Genomes from 27 species used in whole genome compar-
isons were downloaded from ensembl (bacteria.ensembl.org),
and the Uniprot taxon identification numbers are listed in
Table 1. Gene multiple alignments were constructed using
clustalw2 [27] for 16S rRNA and MACSE software [28] for
rpoB sequences. Raxml software [29] was used to construct
the best scoring maximum likelihood tree, which was rooted
using the Corynebacterium glutamicum (strain: ATCC 13032)
reference sequence, an organism closely related to the
mycobacterium genus [30]. Pairwise gene alignments were
constructed using MACSE software, which uses the trans-
lated amino acid sequence and accounts for frame shifts
and premature stop codons. Sequence identities were calcu-
lated using the SIAS webserver. Gaps were not used in the
calculation of the percent identity. Whole genome align-
ments were constructed using mercator and mavid programs
[31], and the resulting homology map was inspected and
drawn using CIRCOS [32]. Orthologue clusters were created
using OrthoMCL [33]. To identify any protein coding genes
under selective pressure across M. aurum, M. tuberculosis,
Mycobacterium bovis – BCG, M. smegmatis, and M. leprae, the
Ka/Ks ratio was calculated, where Ka is the number of non-
synonymous substitutions per non-synonymous site, and
Ks is the number of synonymous substitutions per synony-
mous site. Ratio values less than one imply stabilizing or
purifying selection, whilst values greater than one imply
positive selection. To measure the degree of polymorphism
across the genes, the nucleotide diversity (p) was also calcu-
lated using the same mycobacterial sample alignments. The
Ka/Ks and p metrics were calculated using variscan (http://
www.ub.edu/softevol/variscan) and PAML (http://abacus.
gene.ucl.ac.uk/software/paml.html) software, respectively.obacterium aurum, a potential model organism for investigating drugs
ycobacteriol. (2015), http://dx.doi.org/10.1016/j.ijmyco.2015.05.001
Table 1 – Genomic characteristics of M. aurum in the context of related species.
Organism Chromosome
accession number
Uniprot Strain
taxon id
Assembled
genome (bp)
G + C content No. genes Relative in vitro
growth rate
ACDP risk classa
M. leprae AL450380.1 272631 3268203 57.80 1605 Unculturable 3
C. glutamicum HE802067.1 1204414 3309401 53.81 3099 Rapid 1
M. bovis BX248333 233413 4345492 65.63 3952 Slow 3
M. tuberculosis AL123456.3 83332 4411532 65.61 4047 Slow 3
M. xenopi AJFI01000000 1150591 4434836 66.11 4281 Slow 2
M. canetti HE572590.1 1048245 4482059 65.62 3981 Slow 3
M. thermoresistibile AGVE01000000 1078020 4870742 69.02 4614 Rapid 1
M. hassiacum AMRA01000000 1122247 5000164 69.46 4959 Rapid 1
M. abscessus CU458896.1 36809 5067172 64.15 4942 Rapid 1
M. inracellulare CP003322.1 487521 5402402 68.10 5144 Slow 2
M. neoaurum CP006936.1 700508 5438192 66.88 4217 Rapid 1
M. avium CP000479.1 243243 5475491 68.99 5120 Slow 2
M. gilvum CP002385.1 278137 5547747 67.86 5349 Rapid 1
M. colombiense AFVW02000000 1041522 5579559 68.09 5197 Slow 1
M. indicus pranii CP002275.1 1232724 5589007 68.03 5254 Rapid 1
M. ulcerans CP000325.1 362242 5631606 65.47 4160 Slow 3
M. yongonense CP003347.1 1138871 5662088 67.90 5390 Slow 1
M. phlei AJFJ01000000 1150599 5681954 69.21 5435 Rapid 1
M. aurum TBAb TBA 6019822 67.52 5684 Rapid 1
M. vaccae ALQA01000000 1194972 6245372 68.60 5949 Rapid 1
M. chubuense CP003053.1 710421 6342624 68.29 5843 Rapid 1
M. fortuitum ALQB01000000 1214102 6349738 66.21 6241 Rapid 2
M. vanbaalenii CP000511.1 350058 6491865 67.79 5979 Rapid 1
M. parascrofulaceum ADNV01000000 525368 6564171 68.45 6456 Slow 1
M. kansasii CP006835.1 557599 6577228 66.23 5866 Slow 2
M. marinum CP000854.1 216594 6636827 65.73 5452 Slow 2
M. smegmatis CP000480.1 246196 6988209 67.40 6938 Rapid 1
M. rhodesiae AGIQ01000000 931627 7281599 66.07 7024 Rapid 1
a UK Advisory Committee on Dangerous Pathogens (ACDP) http://www.hse.gov.uk/pubns/misc208.pdf.
b ENA number ERP009288.
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The M. aurum genome
A total of 5.5 million high quality paired end (101 bp) reads
were used to assemble the M. aurum genome. The final M.
aurum assembly consisted of 46 contigs, 43 of which were
over 500 bp in length. The median contig length (N50) was
265 Kb (minimum 315 bp, maximum 742,983 bp). The total
genome length (6.02 Mb, G + C content 67.52%) is longer
than M. tuberculosis (4.4 Mbp) and Mycobacterium canetti
(4.5 Mbp), but shorter than Mycobacterium marinum (6.6 Mbp)
and M. smegmatis (7.0 Mbp) (Table 1). A total of 5684 coding
sequences, 1 tmRNA, 4 rRNA and 51 tRNA features were anno-
tated, and of these 4306 (75%) were assigned a function
(Fig. 1). The final contigs and annotation are available for
download (pathogenseq.lshtm.ac.uk/m_aurum).
M. aurum and the mycobacteria phylogeny
A phylogenetic analysis using 27 mycobacterial whole gen-
ome sequences revealed that M. aurum clustered with
Mycobacterium vaccae and Mycobacterium vanbaalenii within a
clade related to fast-growing mycobacteria (Fig. 2). Slow-
growing bacteria, including M. tuberculosis, clustered withinFig. 1 – An annotated circular view of the M. aurum genome (leng
the 46 contigs, alternating between brown and orange with gre
outer track: the 5684 forward and reverse genes.
Please cite this article in press as: J Phelan et al. The draft genome of Myc
against Mycobacterium tuberculosis and Mycobacterium leprae. Int. J. Ma distinct clade. However, Mycobacterium indicus pranii, a
fast-growing mycobacterium and immunotherapy and vac-
cine candidate for leprosy and tuberculosis [34], clustered
within the slow-growing clade. The very high bootstrap sup-
port values for the phylogenetic tree (median 100%, range
77–100%) indicates the high precision afforded when using
whole genome data. Previously, hsp65, sodA, recA, rpoB and
16S rRNA gene sequence data were used to barcode bacteria,
with the latter approach being adopted widely [35]. The
assembled 16S rRNA sequence for M. aurum had the highest
identity with M. vanbaalenii (99%), Mycobacterium rhodesiae
(99%), and Mycobacterium austroafricanum (99%), in concor-
dance with previous reports [36,37]. The phylogenetic tree
constructed using 16S rRNA sequences was broadly similar
to that from whole genome data (Supplementary Fig. 1).
However, M. aurum and M. vanbaalenii clustered closer to
Mycobacterium abscessus rather than Mycobacterium gilvum,
and the topology was less robust with lower bootstrap sup-
port values.
Comparison to the M. tuberculosis and M. leprae genomes
The M. aurum assembled contigs were ordered according to
the M. tuberculosis H37Rv reference genome (AL123456.3),
leading to 10 gapped scaffolds. Most of the M. tuberculosisth 6.02 Mb). Innermost track: G + C% content; middle track:
en and grey lines representing tRNA and rRNA, respectively;
obacterium aurum, a potential model organism for investigating drugs
ycobacteriol. (2015), http://dx.doi.org/10.1016/j.ijmyco.2015.05.001
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described in Table 1.
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4 June 2015genome (86%) had regions with synteny inM. aurum. The map
of homology between the 10 M. aurum scaffolds and the M.
tuberculosis genome consisted of 67 regions of synteny
(Supplementary Table 2 and Fig. 3a). Although there was high
similarity between M. aurum and M. tuberculosis, there was
evidence for large-scale rearrangements (Fig. 3a). Twenty-
eight genes required for survival within macrophages were
observed, but a further two (lpqY and eccA1) could not be
found [38] (Supplementary Table 3). The putative proteome
for M. aurum suggests it lacks 1002 proteins present in M.
tuberculosis, but has an additional 2090 proteins not seen in
M. tuberculosis (see Table 2).
The map of homology between the 10 M. aurum scaffolds
and theM. leprae genome consisted of 73 segments of synteny
(Supplementary Table 2 and Fig. 3b). For M. aurum and M.
leprae there were 2047 and 222 unique proteins, respectively,
which had no orthologue in the other mycobacteria (see
Supplementary Table 2). M. smegmatis is often used as a
fast-growing model of M. tuberculosis. A similar analysis car-
ried out between M. tuberculosis and M. smegmatis revealed
979 and 2314 unique proteins for each, respectively, which
had no orthologue in the other mycobacteria. When com-
pared with the M. aurum–M. tuberculosis analysis, the number
of apparently unique proteins in M. smegmatis was higher by
224 proteins.Please cite this article in press as: J Phelan et al. The draft genome of Myc
against Mycobacterium tuberculosis and Mycobacterium leprae. Int. J. MDrug resistance candidate genes
Pairwise alignments were constructed for the known drug tar-
get genes to establish the degree of homology between M.
aurum and M. tuberculosis (Table 2). The sequence identity at
the DNA level varied from 68.6% for pncA (pyrazinamide
drug-related) to 96.2% for rrs (streptomycin, capreomycin).
The percentage of amino acid identity was higher than the
sequence identity, being high among all drug resistance can-
didate genes analysed (range 90.6–99.2%). Interestingly, two
genes at different locations were annotated as katG in the
M. aurum genome, and denoted as katG1 and katG2. The per-
cent identity between the two genes and their M. tuberculosis
homologue at the DNA level are 73.6% and 68.8%
(Supplementary Fig. 2) The putative M. aurum katG1 found
in contig 20 (aurum03417) demonstrated the highest homol-
ogy to the M. tuberculosis katG gene (Rv1908c) and M. smegma-
tis MSMEG_6384. The second M. aurum katG2 (aurum 02416)
located in contig 2 (katG2) was most homologous with M.
smegmatis MSMEG_3461. A third M. smegmatis gene,
MSMEG_3729, showed weak homology to each of the katG
genes in M. aurum and M. tuberculosis. Two copies of embB, a
gene associated with ethambutol in M. tuberculosis, were also
found in different locations in M. aurum (72.3% and 47.7%
identity). The semi-identical duplications for each of katGobacterium aurum, a potential model organism for investigating drugs
ycobacteriol. (2015), http://dx.doi.org/10.1016/j.ijmyco.2015.05.001
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Fig. 3 – Homology between M. aurum and M. tuberculosis and M. leprae. (a) M. aurum (green) and M. tuberculosis H37Rv (blue).
The ten contigs provide 67 segments of synteny with M. tuberculosis H37Rv. The segments range from 2,266 bp to 391,674 bp
in length. (b) M. aurum (green) and M. leprae (blue). The ten contigs provide 73 segments of synteny with M. leprae. The
segments range from 2,495 bp to 193,922 bp in length.
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(Supplementary Table 4).
Across a range of therapeutic agents, potential differences
in minimum inhibitory concentration (MIC) levels betweenM.
tuberculosis (H37Rv) and M. aurum for isoniazid, ethambutol
and ofloxacin (Table 2) are available [8,18], with the biggest
difference for isoniazid. The MIC values for isoniazid were
greatest in M. smegmatis (2 mg/L), followed by M. aurum (0.4)
and M. tuberculosis (0.02–0.2). No known M. tuberculosis muta-
tions were identified in the katG, inhA (isoniazid), ethA, ethR
(ethambutol), and gyrA/B (ofloxacin) orthologues in M. aurum.Please cite this article in press as: J Phelan et al. The draft genome of Myc
against Mycobacterium tuberculosis and Mycobacterium leprae. Int. J. MHomologues of ahpC and embR genes, associated with isoni-
azid and ethambutol drug resistance respectively, were not
observed in the M. aurum genome.
The alignments were compared across M. aurum, M. tuber-
culosis, M. bovis – BCG, M. smegmatis, and M. leprae at the loci
considered drug targets or those loci considered to have
important functional roles (Table 3). All loci had a high per-
centage (90%) of their nucleotides analyzable across the
mycobacteria, except fas and gyrA where there were large
insertions in M. aurum and M. leprae, respectively. Only three
loci did not have alignment gaps: inhA (isoniazid drug-obacterium aurum, a potential model organism for investigating drugs
ycobacteriol. (2015), http://dx.doi.org/10.1016/j.ijmyco.2015.05.001
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4 June 2015related); rpsL (streptomycin); and kasA (thiolactomycin). The
ddn (delamanid), fpol1 (para-aminosalicylic acid), murC/D/E/F
family (isoquinolines), and nat (cholesterol metabolism) loci
were the most polymorphic (>40% sites segregating, nucleo-
tide diversity p > 0.2). In contrast, the rrs gene associated with
streptomycin drug resistance was the most conserved (2.9%
segregating sites, pairwise diversity p = 0.029). In general,
there was a modest degree of conservation in most genes
(all with >50% of sequence conserved), which would be
expected given the known synergistic drug effects across
mycobacteria. All candidate genes reported Ka/Ks values
much lower than 1, consistent with the selective removal of
alleles that are deleterious (purifying selection). The highest
Ka/Ks value was observed for nat (Rv3566c), a gene encodingPlease cite this article in press as: J Phelan et al. The draft genome of Myc
against Mycobacterium tuberculosis and Mycobacterium leprae. Int. J. Marylamine acetylase that is associated with resistance to iso-
niazid [39].
Discussion
The draft genome sequence of M. aurum (length 6.02 Mb,
G + C content 67.52%) has been assembled. The genome
assembly consists of 46 contigs and provides the first insight
into the genetic code of M. aurum. Lack of alternative
sequence data for this bacterium, particularly from technolo-
gies with longer reads, prevents closure of the gaps at this
time. Using whole genome alignments, the placement of M.
aurum within the mycobacterial phylogeny, close to M. vaccae
and M. vanbaalenii, was confirmed. The analysis of lociobacterium aurum, a potential model organism for investigating drugs
ycobacteriol. (2015), http://dx.doi.org/10.1016/j.ijmyco.2015.05.001
Table 2 – Drug minimum inhibitory concentrations (MICs) and candidate resistance gene identity between M. aurum and M.
tuberculosis at drug resistance loci.
Drug MICb M. aurum
mg/L (lM)
MICb H37Rv
mg/L (lM)
M. tb loci Gene homology
with M. aurum (%)
Protein similarity
score (%)
M. aurum
feature
Isoniazid katGa 72.06 93.23 2 loci
0.40 0.02–0.2 inhAa 87.40 98.14
(3.65) (0.15–1.46) ahpC – – Absent
kasA 86.33 99.04
Rifampicin 0.10 0.10 rpoBa 90.74 97.62
(0.12) (0.12) rpoC 90.20 98.10
Ethambutol embB 69.87 91.46 2 loci
0.5 0.47 embA 68.87 94.28
(2.45) (2.30) embC 73.83 93.78
embR – – Absent
Streptomycin,
aminoglycosides,
capreomycin
0.2 (0.34) 0.1–0.5 (0.17–0.86) rrs – –
– – rpsL 96.00 99.20
– – tlyA 73.58 92.98
Pyrazinamide >100, >100 pncA 64.17 90.62
(812.26) (812.26) rpsA 93.56 98.55
Ethionamide 5 0.6–2.5 ethA 65.71 94.30
(30.08) (3.6–15.04) ethR 69.15 93.11
Ofloxacin 0.2 1–2 gyrA 90.34 97.75
(0.55) (2.77–5.53) gyrB 86.39 92.30
Homology as calculated using protein alignment. Protein similarity is quite high for most proteins analysed.
a Selected alignments can be found in http://pathogenseq.lshtm.ac.uk/m_aurum/.
b MIC value Ref. [18].
Table 3 – A comparison across M. aurum, M. tuberculosis, M. bovis – BCG, M. smegmatis, and M. leprae alignments at drug
targets or other important loci.
Drug resistance or function Gene name Alignment
lengtha
% Sites
analysedb
Gaps % Segregating
sites
% Conserved
sites
pc Ka/Ksd
Bedaquiline (TMC207) atpE 261 94.25 15 28.0 72.0 0.150 0.089
BTZ043, DNB1, VI-9376, 377790, TCA1 dprE1 1410 98.09 27 34.6 65.4 0.210 0.128
Cholesterol metabolism hsaA 1191 99.50 6 27.6 72.4 0.166 0.150
hsaB 570 98.95 6 26.2 73.8 0.157 0.182
hsaC 903 99.67 3 30.1 69.9 0.182 0.104
hsaD 921 93.81 57 30.9 69.1 0.189 0.129
nat 861 95.82 36 43.8 56.2 0.268 0.287
Fluoro-quinolones gyrA 3807 65.33 1320 32.2 67.8 0.171 0.070
gyrB 2157 93.88 132 36.2 63.8 0.193 0.077
Isoniazid/pyridomycin inhA 810 100 0 28.1 71.9 0.152 0.101
Isoquinolines murC 1512 94.64 81 43.1 56.9 0.235 0.170
murD 1509 96.02 60 46.1 53.9 0.254 0.240
murE 1653 91.83 135 48.1 51.9 0.267 0.228
murF 1617 91.65 135 42.7 57.3 0.230 0.167
Isoxyl (thiocarlide) fas 10701 85.79 1521 37.0 63.0 0.195 0.163
PA-824, delamanid (OPC67683) ddn 513 88.30 60 44.6 55.4 0.280 0.331
para-aminosalicylic acid folP1 882 92.18 69 42.9 57.1 0.241 0.144
folP2 957 88.71 108 35.8 64.2 0.198 0.129
Q203, IP3 qcrB 1695 96.46 60 31.5 68.5 0.174 0.126
Rifampicin rpoB 3537 98.47 54 23.7 76.3 0.128 0.084
Streptomycin rpsL 375 100 0 23.2 76.8 0.122 0.028
rrs 1563 95.84 65 2.9 97.1 0.029 0.029
Thiolactomycin kasA 1251 100 0 29.1 70.9 0.159 0.100
kasB 1326 91.63 111 36.4 63.6 0.195 0.117
Selected alignments can be found at pathogenseq.lshtm.ac.uk/m_aurum/.
a The total number of columns in the alignment including gaps.
b A function of the number of sites used in determining the number of segregating and conserved sites.
c p nucleotide diversity.
d The Ka/Ks is the ratio of the number of non-synonymous substitutions per non-synonymous site (Ka) to the number of synonymous
substitutions per synonymous site (Ks).
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4 June 2015involved in drug resistance demonstrated homology with M.
tuberculosis and M. leprae. This insight corroborates earlier
investigations of inhA gene mutants of M. aurum that showed
similarity in drug resistance mechanisms against isoniazid
and ethionamide between M. aurum and M. tuberculosis
[6,40]. The draft M. aurum genome is larger than that of M.
tuberculosis with an additional 2090 genes not observed in M.
tuberculosis; it is also lacking 1002 of the genes found in M.
tuberculosis. Multiple copies of some homologous genes were
observed. Of particular interest are two putative copies of
embB, a gene involved in the biosynthesis of the mycobacte-
rial cell wall component arabinan and that is associated with
resistance to ethambutol in M. tuberculosis. Similarly, two
annotated catalase-peroxidase (katG) genes that may be
involved in the activation of the anti-tuberculosis pro-drug
isoniazid were identified and confirmed. Multiple katG genes
have been reported in other mycobacteria, for example in
Mycobacterium fortuitum [41]. It could be hypothesized that
the duplications of katG in M. aurum and M. smegmatis could
have an effect on the MIC values. Further laboratory work is
underway to elucidate the endogenous function of the
observed duplications.
In summary, these genomic analyses support the use ofM.
aurum as a potential model organism for providing insights
into M. tuberculosis biology, particularly for new drug develop-
ment, with the possibility of leading to new control measures
for tuberculosis disease. Further insight may be gained from
the genome sequence of additional strains and related
mycobacteria.
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